TNX-1300 is under clinical development by Tonix Pharmaceuticals Holding and currently in Phase II for Substance (Drug) Abuse. According to GlobalData, Phase II drugs for Substance (Drug) Abuse have a 21% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how TNX-1300’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
TNX-1300 overview
TNX-1300 is under development for the treatment of cocaine abuse (intoxication or overdose). The drug candidate is a mutant form of T172R/G173G cocaine esterase. It is administered as an infusion through intravenous route. The drug candidate is an investigational new biologic entity.
Tonix Pharmaceuticals Holding overview
Tonix Pharmaceuticals Holding (Tonix) is a developer of pharmaceutical products to address public health challenges. The company offers pharmaceutical products and treatments for disorders of the central nervous system including fibromyalgia, post traumatic stress disorder and episodic tension-type headache. Its products include oral formulation, smallpox vaccine, disintegrating sublingual tablets and tonmya. Tonix’s tonmya is a lead product candidate, designed as a bedtime treatment for post traumatic stress disorder. Its disintegrating sublingual tablets contain a dose and formulation of cyclobenzaprine and is used for the treatment of fibromyalgia and post-traumatic stress disorder. It markets its products through a network of distributors across the US. It has operations in Ireland, Canada and the US. Tonix is headquartered in New York, the US
For a complete picture of TNX-1300’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
